Physician profile
Mudusar I Raza
NPI 1467562371
$4,617.23
in general payments reported to CMS, 2019-2025
24 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $1,220 · 2024: $1,530 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,213 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,212.96 |
| Travel and Lodging | $225.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,520.61 | 2022-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $707.90 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.46 | 2023-2025 | Ofev, Stiolto Respimat, Jascayd |
| Regeneron Healthcare Solutions, INC. | $284.53 | 2022-2024 | Dupixent |
| Olympus Corporation of The Americas | $249.07 | 2025 | |
| Inspire Medical Systems, INC. | $212.81 | 2023-2024 | Inspire |
| Axsome Therapeutics, INC. | $138.78 | 2024-2025 | Sunosi |
| Harmony Biosciences LLC | $132.43 | 2023-2024 | Wakix |
| Viatris Specialty LLC | $112.13 | 2025 | Yupelri |
| Grifols USA, LLC | $101.91 | 2024-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $90.48 | 2023-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $89.82 | 2024-2025 | Opsumit, Opsynvi, Uptravi |
| Electromed, INC. | $72.71 | 2023-2024 | Smartvest |
| Intuitive Surgical, INC. | $71.85 | 2024 | |
| Jazz Pharmaceuticals INC. | $71.18 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $61.00 | 2023-2024 | Acthar |
| Insmed, INC. | $60.50 | 2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $57.74 | 2024-2025 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $43.10 | 2024-2025 | Lumryz |
| Verona Pharma, INC. | $38.38 | 2025 | Ohtuvayre |
| Amgen INC. | $36.21 | 2023-2024 | Tezspire |
| Baxter Healthcare | $34.68 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $30.34 | 2024 | Yupelri |
| Genzyme Corporation | $18.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mudusar Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.